NO20006451L - Inhibitorer av transkripsjonsfaktor NF-kB - Google Patents
Inhibitorer av transkripsjonsfaktor NF-kBInfo
- Publication number
- NO20006451L NO20006451L NO20006451A NO20006451A NO20006451L NO 20006451 L NO20006451 L NO 20006451L NO 20006451 A NO20006451 A NO 20006451A NO 20006451 A NO20006451 A NO 20006451A NO 20006451 L NO20006451 L NO 20006451L
- Authority
- NO
- Norway
- Prior art keywords
- present
- disease
- transcription factor
- inhibitors
- activation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8982798P | 1998-06-19 | 1998-06-19 | |
PCT/US1999/013652 WO1999065449A2 (en) | 1998-06-19 | 1999-06-18 | INHIBITORS OF TRANSCRIPTION FACTOR NF-λB |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20006451D0 NO20006451D0 (no) | 2000-12-18 |
NO20006451L true NO20006451L (no) | 2000-12-18 |
Family
ID=22219773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20006451A NO20006451L (no) | 1998-06-19 | 2000-12-18 | Inhibitorer av transkripsjonsfaktor NF-kB |
Country Status (21)
Country | Link |
---|---|
US (3) | US6492425B1 (es) |
EP (1) | EP1085848B1 (es) |
JP (1) | JP2002518307A (es) |
KR (1) | KR20010052991A (es) |
CN (1) | CN1311629A (es) |
AR (1) | AR019692A1 (es) |
AT (1) | ATE383769T1 (es) |
AU (1) | AU4690099A (es) |
BR (1) | BR9911152A (es) |
CA (1) | CA2335294A1 (es) |
CO (1) | CO5021213A1 (es) |
CZ (1) | CZ20004761A3 (es) |
DE (1) | DE69937997T2 (es) |
ES (1) | ES2299251T3 (es) |
HU (1) | HUP0102782A3 (es) |
IL (1) | IL140328A0 (es) |
NO (1) | NO20006451L (es) |
PL (1) | PL348969A1 (es) |
TR (1) | TR200003781T2 (es) |
WO (1) | WO1999065449A2 (es) |
ZA (1) | ZA200007447B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4138013B2 (ja) | 1996-12-23 | 2008-08-20 | イミュネックス・コーポレーション | Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
DE69939822D1 (de) | 1998-05-14 | 2008-12-11 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
GB9930616D0 (en) * | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
EP1134221A1 (en) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
FR2813315B1 (fr) | 2000-08-23 | 2002-10-18 | Genfit S A | Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha |
US8263657B2 (en) * | 2000-12-18 | 2012-09-11 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
JP4599501B2 (ja) * | 2001-11-07 | 2010-12-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 多発性骨髄腫および他の癌の処置におけるIκBのインヒビターとしてのカルボリン誘導体 |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
CA2487900A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
EA008769B1 (ru) * | 2002-06-05 | 2007-08-31 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения диабета |
CN1658855B (zh) * | 2002-06-06 | 2010-04-28 | 株式会社医药分子设计研究所 | O-取代羟基芳基衍生物 |
EP1514544A4 (en) * | 2002-06-06 | 2009-01-07 | Inst Med Molecular Design Inc | HYPO-ALLERGENIC |
EP1535610A4 (en) * | 2002-06-10 | 2008-12-31 | Inst Med Molecular Design Inc | THERAPEUTIC CANCER |
WO2003103654A1 (ja) * | 2002-06-10 | 2003-12-18 | 株式会社医薬分子設計研究所 | NF−κB活性化阻害剤 |
AU2003242124A1 (en) * | 2002-06-11 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of neurodegenerative diseases |
US7324455B2 (en) | 2003-03-14 | 2008-01-29 | International Business Machines Corporation | Transfer of error-analysis and statistical data in a fibre channel input/output system |
US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
US20050256132A1 (en) * | 2003-04-30 | 2005-11-17 | Wyeth | Use of ER selective NF-kB inhibitors for the treatment of sepsis |
US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
CN1826121B (zh) * | 2003-07-23 | 2013-05-29 | 幸讬制药公司 | 苯基与吡啶基衍生物用于制备调控钙离子释放活化钙离子通道的药物的用途 |
US7425580B2 (en) | 2004-05-19 | 2008-09-16 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
US20080207673A1 (en) * | 2005-05-04 | 2008-08-28 | Michel Xilinas | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins |
CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
US7671058B2 (en) * | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
JP5470046B2 (ja) | 2007-10-23 | 2014-04-16 | 株式会社医薬分子設計研究所 | Pai−1産生抑制剤 |
JP2011500853A (ja) | 2007-10-25 | 2011-01-06 | ファィトシューティカ, インコーポレイテッド | 炎症性腸疾患および/または過敏性腸管症候群に対する処置としてのphy906の使用 |
US8609730B2 (en) * | 2008-01-08 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
US20090264514A1 (en) * | 2008-04-18 | 2009-10-22 | The Research Foundation Of State University Of New York | SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY |
US10640457B2 (en) | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
CN103347392B (zh) | 2010-12-22 | 2016-10-12 | 纽约市哥伦比亚大学理事会 | 组蛋白乙酰转移酶调节剂和其用途 |
TWI492920B (zh) * | 2012-04-18 | 2015-07-21 | Nat Defense Medical Ct | 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途 |
WO2014113467A1 (en) | 2013-01-15 | 2014-07-24 | Board Of Regents, The University Of Texas System | Stat3 inhibitor |
CN114621346A (zh) * | 2013-08-21 | 2022-06-14 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
US20170182054A1 (en) * | 2014-03-31 | 2017-06-29 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
EP3338783B1 (en) | 2014-09-12 | 2024-01-24 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
CN105797154B (zh) * | 2014-12-31 | 2020-03-10 | 中国科学院上海生命科学研究院 | 软骨干细胞的分离及其应用 |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
WO2017122209A2 (en) * | 2016-01-12 | 2017-07-20 | Yeda Research And Development Co. Ltd. | NF-kappaB INHIBITORS |
CN116672445A (zh) | 2016-02-26 | 2023-09-01 | 德克萨斯大学体系董事会 | 连接蛋白(Cx)43半通道结合抗体及其用途 |
GB201604484D0 (en) * | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
WO2018173069A1 (en) | 2017-03-21 | 2018-09-27 | Novalead Pharma Inc. | Therapeutic agent for phosphodiesterase inhibition and its related disorders |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
BR112022009457A2 (pt) * | 2019-11-18 | 2022-08-16 | Univ California | Inibidores duplos de receptor androgênico/akr1c3 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1079177A (en) * | 1963-06-11 | 1967-08-16 | Stecker Internat S P A | Improvements in pesticide composition for destroying internal worm parasites in animals |
GB1079178A (en) * | 1966-07-27 | 1967-08-16 | Stecker Internat S P A | Improvements in pesticide compositions for destroying internal worm parasites in animals |
US4742083A (en) * | 1983-08-24 | 1988-05-03 | Lever Brothers Company | Method of relieving pain and inflammatory conditions employing substituted salicylamides |
US4803279A (en) * | 1985-05-23 | 1989-02-07 | Smithkline Beckman Corporation | 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines. |
ES2072015T3 (es) | 1990-08-21 | 1995-07-01 | Upjohn Co | Derivados del acido bisfosfonico como agente anti-artritico. |
EP0584238A1 (en) * | 1991-05-17 | 1994-03-02 | Chiron Corporation | INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF |
US5466715A (en) * | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
DE4200534A1 (de) * | 1992-01-11 | 1993-07-15 | Henkel Kgaa | Neue n-benzyl-4-aminophenole und deren verwendung als entwicklerkomponente in oxidationshaarfaerbemitteln |
WO1994028887A1 (en) * | 1993-06-15 | 1994-12-22 | The Australian National University | Synergistic anthelmintic compositions |
JP2001513503A (ja) * | 1997-08-06 | 2001-09-04 | スミスクライン・ビーチャム・コーポレイション | 心臓血管系の疾病の治療に用いられるマクロファージスカベンジャー受容体アンタゴニスト |
-
1998
- 1998-06-19 HU HU0102782A patent/HUP0102782A3/hu unknown
-
1999
- 1999-06-18 AU AU46900/99A patent/AU4690099A/en not_active Abandoned
- 1999-06-18 KR KR1020007014386A patent/KR20010052991A/ko not_active Application Discontinuation
- 1999-06-18 ES ES99930345T patent/ES2299251T3/es not_active Expired - Lifetime
- 1999-06-18 DE DE69937997T patent/DE69937997T2/de not_active Expired - Fee Related
- 1999-06-18 CO CO99038264A patent/CO5021213A1/es unknown
- 1999-06-18 AT AT99930345T patent/ATE383769T1/de not_active IP Right Cessation
- 1999-06-18 CN CN99807571A patent/CN1311629A/zh active Pending
- 1999-06-18 BR BR9911152-7A patent/BR9911152A/pt not_active Application Discontinuation
- 1999-06-18 WO PCT/US1999/013652 patent/WO1999065449A2/en active IP Right Grant
- 1999-06-18 IL IL14032899A patent/IL140328A0/xx unknown
- 1999-06-18 CA CA002335294A patent/CA2335294A1/en not_active Abandoned
- 1999-06-18 AR ARP990102955A patent/AR019692A1/es unknown
- 1999-06-18 TR TR2000/03781T patent/TR200003781T2/xx unknown
- 1999-06-18 PL PL99348969A patent/PL348969A1/xx unknown
- 1999-06-18 EP EP99930345A patent/EP1085848B1/en not_active Expired - Lifetime
- 1999-06-18 US US09/720,018 patent/US6492425B1/en not_active Expired - Fee Related
- 1999-06-18 JP JP2000554329A patent/JP2002518307A/ja not_active Withdrawn
- 1999-06-18 CZ CZ20004761A patent/CZ20004761A3/cs unknown
-
2000
- 2000-12-13 ZA ZA200007447A patent/ZA200007447B/en unknown
- 2000-12-18 NO NO20006451A patent/NO20006451L/no not_active Application Discontinuation
-
2002
- 2002-07-31 US US10/210,560 patent/US20030092771A1/en not_active Abandoned
-
2005
- 2005-10-03 US US11/242,572 patent/US20060035979A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4690099A (en) | 2000-01-05 |
WO1999065449A2 (en) | 1999-12-23 |
DE69937997D1 (es) | 2008-03-06 |
ATE383769T1 (de) | 2008-02-15 |
AR019692A1 (es) | 2002-03-13 |
TR200003781T2 (tr) | 2001-07-23 |
NO20006451D0 (no) | 2000-12-18 |
US20030092771A1 (en) | 2003-05-15 |
PL348969A1 (en) | 2002-06-17 |
DE69937997T2 (de) | 2009-02-19 |
ZA200007447B (en) | 2002-02-13 |
EP1085848B1 (en) | 2008-01-16 |
EP1085848A2 (en) | 2001-03-28 |
EP1085848A4 (en) | 2004-09-08 |
KR20010052991A (ko) | 2001-06-25 |
ES2299251T3 (es) | 2008-05-16 |
US20060035979A1 (en) | 2006-02-16 |
BR9911152A (pt) | 2001-03-06 |
WO1999065449A3 (en) | 2000-03-30 |
CO5021213A1 (es) | 2001-03-27 |
US6492425B1 (en) | 2002-12-10 |
CN1311629A (zh) | 2001-09-05 |
CA2335294A1 (en) | 1999-12-23 |
HUP0102782A2 (hu) | 2001-12-28 |
HUP0102782A3 (en) | 2002-12-28 |
JP2002518307A (ja) | 2002-06-25 |
CZ20004761A3 (cs) | 2001-08-15 |
WO1999065449A8 (en) | 2001-03-08 |
IL140328A0 (en) | 2002-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20006451L (no) | Inhibitorer av transkripsjonsfaktor NF-kB | |
NO995543L (no) | Monoestere fra probukol for behandling av kardiovaskulær og inflammatorisk sykdom | |
CY1108301T1 (el) | Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση | |
HUP0303040A2 (hu) | Készítmények és eljárások a plazma lipoprotein szintjének és a cardiovascularis betegségek kockázati tényezőinek csökkentésére | |
MXPA06000326A (es) | Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones. | |
HK1046413B (zh) | 作為環加氧酶-2-抑制劑的4,5二芳基-3(2h)-呋喃酮衍生物 | |
FI945556A0 (fi) | Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset | |
TW200505449A (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
MXPA01007335A (es) | Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4). | |
DE69332762D1 (de) | Cathecoldiether als selektive pde iv hemmungsmittel | |
GB0220187D0 (en) | Organic compounds | |
YU64100A (sh) | Postupak za sintetizovanje cox-2 inhibitora | |
WO1997018207A3 (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
NO20006452L (no) | Inhibitorer av transkripsjonsfaktor NF-kB | |
AU2002363182A1 (en) | Smad7 inhibitors for the treatment of cns diseases | |
EP1461313A4 (en) | INHIBITORS OF HUMAN ADAM-10 | |
WO2003106450A8 (de) | Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren | |
HUP0402577A2 (hu) | Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra | |
MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
NO20053341L (no) | Hindring og behandling av Alzheimers sykdom. | |
DE69810100D1 (de) | Macrocyclische verbindungen als metallproteaseinhibitoren | |
GB0113663D0 (en) | Use of organic compounds | |
ES2119377T3 (es) | Derivados bencisotiazoles inhibidores de la biosintesis de la 5-lipoxigenasa. | |
WO2003026569A3 (en) | Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals | |
EP1692284B8 (de) | Anti-apoptotisch wirksame apatamere |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |